My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

5.959 -0.041 (-0.69%)
Streaming Delayed Price Updated: 9:44 AM EDT, Sep 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
40 41 Next >
Cybin Announces Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plans to Participate in Annual Canaccord Genuity Growth Conference
Via Investor Brand Network
Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Cybin Inc.
Via Business Wire
Analyst Expectations for Cybin's Future
 
Via Benzinga
Cybin: Q4 Earnings Insights
 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Global CRO Partner to Study, Develop CYB003 as Effective MDD Treatment
Via Investor Brand Network
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
Via FinancialNewsMedia
Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials
Cybin One Steps Away From Complete Dosing 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Significant Milestone in Advancing CYB003 Towards Pivotal Studies
Via Investor Brand Network
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
A Quantum Leap In Psychedelic Research: Study Shows Real-Time Brain Changes After Ketamine Use
A newly published study shows that Kernel’s Flow technology system is in fact able to capture and analyze brain changes following the administration of a psychoactive substance. 
Via Benzinga
Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects
Via Investor Brand Network
Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects
From Kernel
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Shares Plans to Develop Scalable Psychedelic Facilitation Training Program
Via Investor Brand Network
Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
From Cybin Inc.
Via Business Wire
Why Caribou Biosciences Shares Are Trading Higher By Around 58%? Here Are Other Stocks Moving In Thursday's Session
Gainers Caribou Biosciences, Inc. (NASDAQ: CRBU) shares jumped 58.1% to $6.45 after the company announced a $25 million equity investment from Pfizer. 
Via Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Names New COO, Announces Participation in Upcoming London Symposium
Via Investor Brand Network
Cybin to Participate in PSYCH Symposium London 2023
From Cybin Inc.
Via Business Wire
Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer
From Cybin Inc.
Via Business Wire
Cybin's FY2023 Financials, Guidance And Appointment Of Sanford R. Climan As Strategic Advisor
Psychedelics biopharma company Cybin Inc. (NYSE: CYBN) shared its financial results for the fiscal year ended this March 31 as well as recent business highlights. Numbers show: Total cash of $12.5... 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases FY 2023 Financial Report, Business Highlights
Via Investor Brand Network
Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Names Seasoned Veteran as Strategic Advisor
Via Investor Brand Network
Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Psychedelic Science 2023 Conference
Via Investor Brand Network
Cybin to Participate in the 2023 MAPS Psychedelic Science Conference
From Cybin Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.